UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases | MicrobiomeTrials← Back to trialsNCT07410377
UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases
WITHDRAWNEARLY_PHASE1INTERVENTIONAL
Trial Details
Start: 2026-03Est. Completion: 2027-03
Enrollment target: 0 participants Locations- The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
Other microbiome trials you might be interested in
Autoimmune Diseases
Background:
Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause t…
Bethesda, United StatesEst. completion Apr 22, 2030
Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Pemphigus VulgarisMultiple Sclerosis (MS)Systemic Sclerosis (SSc)Pediatric SLEJuvenile Idiopathic Arthritis (JIA)Juvenile Dermatomyositis (JDM)Pediatric-Onset Multiple Sclerosis (POMS)
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additio…
Los Angeles, United StatesCompleted Jun 22, 2023
Lupus Erythematosus, Systemic
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell thera…
San Francisco, United StatesEst. completion May 1, 2029